IL25 and breast carcinoma: In estrogen receptor (ER)‐positive breast cancer cells, Shuai et al. have shown that upregulation of ER resulted in an increased expression of IL‐25 in the tumor cells, and expression of IL‐25 in these cells has led to tumor inhibition.27